<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5931">
  <stage>Registered</stage>
  <submitdate>31/03/2016</submitdate>
  <approvaldate>31/03/2016</approvaldate>
  <nctid>NCT02728206</nctid>
  <trial_identification>
    <studytitle>Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation</studytitle>
    <scientifictitle>A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir Fixed Dose Combination Administered for Four Weeks in Patients Infected With Chronic HCV in the Peri-Operative Liver Transplantation Setting</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GS-US-342-2083</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C Virus Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SOF/VEL

Experimental: SOF/VEL - SOF/VEL FDC for 4 weeks starting on the day of or day after the participant's liver transplant


Treatment: drugs: SOF/VEL
SOF/VEL (400/100 mg) FDC tablet administered orally once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) - SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment.</outcome>
      <timepoint>Posttreatment Week 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</outcome>
      <timepoint>Up to 4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4) - SVR4 is defined as HCV RNA &lt; LLOQ at 4 weeks after stopping study treatment.</outcome>
      <timepoint>Posttreatment Week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants With HCV RNA &lt; LLOQ on Treatment</outcome>
      <timepoint>Up to 4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants With Virologic Failure - Virologic failure is defined as HCV RNA = LLOQ at end of treatment or relapse during posttreatment follow-up.</outcome>
      <timepoint>Up to Posttreatment Week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  HCV-infected, male and non-pregnant/non-lactating females, who are undergoing liver
             transplantation

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Receiving an HCV-infected liver

          -  HIV or hepatitis B virus (HBV) co-infected

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>12/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the antiviral efficacy, safety, and tolerability of
      sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in hepatitis C virus
      (HCV)-infected adults who are undergoing liver transplantation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02728206</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Gilead Study Team</name>
      <address />
      <phone>1-833-GILEAD-0(1-833-445-3230)</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>